Download Image
    
Share
  
Post
Diacerein for COVID-19
1 study with 14 patients
Hospital Icon Control
Hospital Icon Diacerein Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Diacerein studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -10% Hospitalization -10% RCTs -10% Late -10% Favorsdiacerein Favorscontrol
Diacerein is an oral, small molecule anti-inflammatory drug that inhibits the interleukin-1β (IL-1β) pathway and inflammasome activation. Recent:
Carmo.
Oct 7
2024
 Carmo et al., Frontiers in Pharmacology, doi:10.3389/fphar.2024.1402032 Diacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study
10% longer hospitalization (p=0.79). RCT 14 hospitalized patients with mild to moderate COVID-19 showing reduced plasma inflammasome markers with diacerein treatment, but no significant difference in duration of hospitalization. The study was halted early due to declining CO..